Metabolic dysfunction- associated steatohepatitis, or MASH, is an inflammatory, liver-scarring disease that has reached epidemic proportions, with an estimated 1.5% to 6.5% of U.S. adults afflicted by ...
Hosted on MSN
MTVA: DA-1241 in Combination with Efruxifermin Shows Additive Hepatoprotective Effects in Mouse MASH Model…
DA-1241 in Combination with Efruxifermin Shows Enhanced Hepatoprotective Effects On June 21, 2025, MetaVia Inc. (NASDAQ:MTVA) announced the presentation of preclinical data for DA-1241, the company’s ...
"[We] have conducted a large individual participant data meta-analysis and shown that screening strategies using sequential application of simple NITs like FIB-4 or NFS followed by LSM-VCTE achieve ...
What Are Clinical Trials for MASH? Clinical trials for MASH are research studies that evaluate potential new treatments for a form of liver disease called metabolic dysfunction-associated ...
HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, announces promising findings from a study utilizing the HepQuant DuO test to evaluate the impact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback